Metallocene-Based Phosphine Ligands for Enantioselective Catalysis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current chiral bisphosphine ligands for enantioselective catalysis do not achieve optimal enantioselectivity in asymmetric transformation reactions, particularly in hydrogenation processes, where high enantiomeric excess is desired.

Innovation Solution

Development of metallocene-based phosphine or arsine ligands with specific structural features, including a metal center, a linker capable of binding to phosphorus or arsenic, and substituents that provide chirality, allowing for the formation of chiral phosphorus or arsenic centers, which are used in transition metal complexes for enhanced enantioselective catalysis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional chiral bisphosphine ligands are used in asymmetric transformation reactions, then the catalytic process can proceed, but the enantioselectivity achieved is suboptimal and does not reach high enantiomeric excess

Engineering Contradiction:
ImproveenantioselectivityVSAvoidligand structure complexity
Core Design Contradiction:
Manufacturing precisionVSDevice complexity

Solution Approach 1:

The patent applies asymmetry by introducing a chiral metallocene framework with specific stereochemical configuration (R or S) at the phosphorus center. The ligand structure incorporates asymmetric elements including a chiral auxiliary group and a metallocene backbone with defined stereochemistry, creating a highly enantioselective catalyst that achieves up to 99% enantiomeric excess in hydrogenation reactions

Inventive Principle:
Principle #4Asymmetry

Solution Approach 2:

The patent applies local quality by optimizing specific regions of the ligand structure: the phosphorus center is configured with specific stereochemistry, the metallocene backbone provides a rigid chiral environment, and substituents at specific positions (R1, R2, R3) are carefully selected to enhance enantioselectivity while maintaining catalytic activity. This localized optimization of structural features achieves high enantioselectivity without requiring complete redesign of the entire ligand system

Inventive Principle:
Principle #3Local quality

2Manufacturing precision

If existing chiral phosphine ligands are used, then the synthesis process is relatively simple, but the enantiomeric excess obtained in hydrogenation reactions is insufficient

Engineering Contradiction:
Improveenantiomeric excessVSAvoidligand synthesis complexity
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent applies preliminary action by pre-configuring the chiral metallocene framework with defined stereochemistry before catalyst formation. The chiral auxiliary and metallocene backbone are synthesized with predetermined absolute configuration, ensuring that the resulting catalyst inherently provides high enantioselectivity. This preliminary establishment of chirality eliminates the need for complex post-synthesis modifications or resolution steps

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent uses the metallocene-based phosphine ligand as an intermediary that transfers chiral information from the ligand structure to the metal center and subsequently to the substrate during catalysis. The ligand acts as a chiral mediator that controls the stereochemical outcome of the hydrogenation reaction, enabling high enantiomeric excess to be achieved through its structured design rather than through complex synthesis procedures

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentUS7906669B2Metallocene-based phosphorus chiral phosphines
Publication Date: 2011.03.15 SOLVIAS AG
  • US7906669B2 patent drawing
  • US7906669B2 patent drawing
  • US7906669B2 patent drawing

AI summary

The present invention concerns a metallocene-based phosphine ligand for use in enantioselective catalysis, the ligand having the Formula (I): Wherein M is a metal; Z is P or As; L is a suitable linker; R1 is selected from alkyl, alkoxy, alkylamino, cycloalkyl, cycloalkoxy, cycloalkylamino carbocyclic aryl, substituted and unsubstituted carbocyclic aryloxy, heteroaryl, heteroaryloxy, carbocyclic arylamino and heteroarylamino; X* is selected from (II): Wherein R, R2 and R3 are independently selected from optionally substituted branched- and straight-chain alkyl, cycloalkyl, heterocycloalkyl, carbocyclic aryl, and heteroaryl.